Measuring the Cost of Liposomal Bupivacaine in Plastic and Reconstructive Surgery: A Scoping Review

Liposomal bupivacaine (LB) is a long-acting analgesic implemented within multimodal and enhanced recovery after surgery (ERAS) pathways in plastic and reconstructive surgery. While it has been popularized as an opioid-sparing alternative for postoperative pain management, LB costs far more to acquire than standard bupivacaine, and its contribution to downstream costs is difficult to isolate. This scoping review mapped the study designs, cost constructs, methods, and results of cost measures linked to LB in plastic and reconstructive surgery. Eligible studies gave LB to patients undergoing plastic and reconstructive surgery and reported at least one quantitative measure of cost or charge. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) and Joanna Briggs Institute (JBI) guidance, MEDLINE, the Cochrane Library, Web of Science, Embase, and ScienceDirect were searched for English-language studies published from January 2012 through August 2024. Data were charted using Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 as an extraction scaffold. As a declared extension of scoping methodology, the cost endpoint was appraised using American Society of Plastic Surgeons and the Oxford Centre for Evidence-Based Medicine (ASPS/OCEBM) levels of evidence, Cochrane risk of bias (RoB) 2 for randomized trials, and Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) for non-randomized studies. Three randomized trials and five non-randomized trials met the inclusion criteria. Cost constructs ranged from drug acquisition price and patient willingness-to-pay to charges derived from hospital length of stay (LOS), cost-to-charge-converted direct costs, data-warehouse costs, and claims costs compared with diagnosis-related group (DRG)-expected values. The only directly comparable element amongst the included studies was the LB acquisition price. This scoping review reveals that the cost evidence for LB in plastic and reconstructive surgery comprises widely heterogeneous endpoints that are not comparable with one another. Economic value-based positioning of LB in multimodal analgesia and ERAS pathways will require further prospective, adequately powered trials and full economic evaluations that declare their perspective, use contemporary comparators, standardize the price year, extend the time horizon beyond the index care event, and report uncertainty.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-11-18
DOI
https://doi.org/10.7759/cureus.119870
Primary Topic
Anesthesia and Pain Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Measuring the Cost of Liposomal Bupivacaine in Plastic and Reconstructive Surgery: A Scoping Review

Nathan S. Berger, Anna Ng-Pellegrino, Leonard J. Auger, Lauren M. Lapsley et al.
2 links
Cureus
Anesthesia and Pain Management
article

Measuring the Cost of Liposomal Bupivacaine in Plastic and Reconstructive Surgery: A Scoping Review

Nathan S. Berger, Anna Ng-Pellegrino, Leonard J. Auger, Lauren M. Lapsley, Olivia Karis Hoy, Isabelle Chalegra Salvador, Kurt R Tio, Maya C Kunsman, Sai Mandalapu
article en

Abstract

Liposomal bupivacaine (LB) is a long-acting analgesic implemented within multimodal and enhanced recovery after surgery (ERAS) pathways in plastic and reconstructive surgery. While it has been popularized as an opioid-sparing alternative for postoperative pain management, LB costs far more to acquire than standard bupivacaine, and its contribution to downstream costs is difficult to isolate. This scoping review mapped the study designs, cost constructs, methods, and results of cost measures linked to LB in plastic and reconstructive surgery. Eligible studies gave LB to patients undergoing plastic and reconstructive surgery and reported at least one quantitative measure of cost or charge. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) and Joanna Briggs Institute (JBI) guidance, MEDLINE, the Cochrane Library, Web of Science, Embase, and ScienceDirect were searched for English-language studies published from January 2012 through August 2024. Data were charted using Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 as an extraction scaffold. As a declared extension of scoping methodology, the cost endpoint was appraised using American Society of Plastic Surgeons and the Oxford Centre for Evidence-Based Medicine (ASPS/OCEBM) levels of evidence, Cochrane risk of bias (RoB) 2 for randomized trials, and Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) for non-randomized studies. Three randomized trials and five non-randomized trials met the inclusion criteria. Cost constructs ranged from drug acquisition price and patient willingness-to-pay to charges derived from hospital length of stay (LOS), cost-to-charge-converted direct costs, data-warehouse costs, and claims costs compared with diagnosis-related group (DRG)-expected values. The only directly comparable element amongst the included studies was the LB acquisition price. This scoping review reveals that the cost evidence for LB in plastic and reconstructive surgery comprises widely heterogeneous endpoints that are not comparable with one another. Economic value-based positioning of LB in multimodal analgesia and ERAS pathways will require further prospective, adequately powered trials and full economic evaluations that declare their perspective, use contemporary comparators, standardize the price year, extend the time horizon beyond the index care event, and report uncertainty.

Cureus
Temple University (US)
Good health and well-being
Anesthesia and Pain Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon